Louise Campbell shares highlights from the recent 5th Global NASH Congress, while Jörn Schattenberg and Roger Green share questions and related comments.
NASH Tsunami covers the 5th Global NASH Congress, with Louise Campbell and Rachel Zayas conducting speaker interviews and Jouise, Rachel, Jörn Schattenberg and Roger Green commenting on conference themes and related areas of interest.
Quentin Anstee joins the Surfers (including Stephen Harrison) to discuss two recent presentations on NITs and to consider how to move discussion of NASH Best Practices around NITs forward.
Quentin Anstee joins the Surfers (including Stephen Harrison) to discuss two recent presentations on NITs and to explore benefits and best ways to “stack” NASH biomarkers to create a more robust efficacy measure for clinical trials.
Quentin Anstee joins the Surfers (including Stephen Harrison) to discuss two recent presentations on NITs and to consider goals and applications for NASH Biomarkers.
Quentin Anstee joins the Surfers (including Stephen Harrison) to discuss Five Key Takeaways in two recent presentations on NITs. He challenges the group to reconsider what NIT (and testing) NASH Best Practices should become.
Quentin Anstee joins the Surfers (including Stephen Harrison) to share lessons about the proper use of non-invasive tests in the clinical trial process and to explore implications for best practices and future research or research.
Surfing the NASH Tsunami shares Dr. Marcelo Kugelmas’s portion of the Madrigal Pharmaceuticals presentation at NAFLD, which covers NAFLD patient screening and diagnostics along with NASH patient management. After this, he answers questions from Roger Green, who then interviews Dr. Naim Alkhouri on disease prevalence and strategies for bringing patient to be tested.
Jörn Schattenberg, Louise Campbell and Roger Green wrap up the discussion of NASH drug development in 2022 by citing their reasons for optimism, ranging from what researchers have proven already about safety and efficacy to the likelihood that combination therapy will eventually become the core therapeutic strategy and the emerging importance of quality of life measures.
Stephen Harrison, Jörn Schattenberg, Louise Campbell and Roger Green all discuss the role that combination NASH drugs and greater population diversity in clinical trials will strengthen NASH drug development.
